Fig. 3: Long-term (weeks 28–100) efficacy endpoints associated with high induction doses of risankizumab at weeks 0, 4, and 16.

a PASI 90 responses. b PASI 100 responses. c PGA 0/1 responses. d PGA 0 responses. e Mean PASI improvement. f Mean PASI. Data are presented as mean ± 95% confidence interval, where error bars are reported.